A double-blind, randomized, placebo-controlled, phase I study to assess the tolerability, safety, pharmacokinetics, and pharmacodynamics of repeated daily doses of 3, 10 and 30mg of macitentan in Korean healthy male subjects.
Latest Information Update: 18 Sep 2019
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 18 Feb 2012 New trial record